The Company’s sales are primarily derived from the manufacture and sale of Human Albumin and Immunoglobulin products. The Company’s sales by significant types of product for the three months ended September 30, 2013 and 2012 are as follows:

	For the three months ended
	September 30, 2013	September 30, 2012
	USD	USD
Human Albumin	26,420,902	22,990,891
Immunoglobulin products:
Human Immunoglobulin for Intravenous Injection	17,162,545	23,412,548
Other Immunoglobulin products	5,355,020	3,685,613
Placenta Polypeptide	2,762,092	2,726,801
Others	1,451,582	308,197
Total	53,152,141	53,124,050

The Company’s sales by significant types of product for the nine months ended September 30, 2013 and 2012 are as follows:

	For the nine months ended
	September 30, 2013	September 30, 2012
	USD	USD
Human Albumin	69,686,924	68,320,593
Immunoglobulin products:
Human Immunoglobulin for Intravenous Injection	63,921,570	59,913,448
Other Immunoglobulin products	15,949,006	14,458,714
Placenta Polypeptide	7,984,246	7,346,812
Others	3,222,650	778,283
Total	160,764,396	150,817,850